Year None2022202120202019201820172016 Date Latest Press Release July 2, 2021 Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) June 29, 2021 Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for the Development and FDA Approval of Zokinvy® (lonafarnib) June 28, 2021 Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session May 26, 2021 Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021 May 6, 2021 Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update May 3, 2021 Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in Brazil April 29, 2021 Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021 April 22, 2021 Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of Directors March 9, 2021 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update February 23, 2021 Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
